Midterm elections changed the balance of power in the healthcare market: what should investors know?

The US midterm elections, in which the Democrats won, are changing the balance of power in the healthcare market. Analysts analyze the effects on pharmaceutical, biotech, and hospital companies, and recommend investors focus on companies less exposed to price pressure, such as medical aesthetics and over-the-counter drugs.

The US midterm elections, in which the Democrats won control of Congress, are expected to change the balance of power in the healthcare market. The article analyzes the expected effects on pharmaceutical, biotech, hospital, and insurance companies, focusing on opportunities and risks for investors. Analysts note that pressure to lower drug prices is likely to increase, but Trump's veto power may block some moves. Conversely, the cancellation of the hospital budget cuts and the restoration of science funding could benefit medical equipment and research companies. Israeli biotech companies may benefit from increased acquisitions by large pharmaceutical companies. However, experts warn of China's growing strength in medical innovation.

Midterm elections changed the balance of power in the healthcare market: what should investors know?